Changes in noradrenergic transmission alter the concentration of cytoplasmic progestin receptors in hypothalamus.
D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects; D003000:Clonidine / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism*; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D007031:Hypothalamus / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism*; D010643:Phenoxybenzamine / Q000494:pharmacology; D011301:Preoptic Area / Q000187:drug effects; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000378:metabolism*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism*; D012726:Sexual Behavior, Animal / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects
D011372:Progestins; D011942:Receptors, Adrenergic, alpha; D011980:Receptors, Progesterone; D010643:Phenoxybenzamine; D011374:Progesterone; D004958:Estradiol; D004299:Dopamine beta-Hydroxylase; D003000:Clonidine; D009638:Norepinephrine